Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Source filing unavailable
Q4 2012 · —
Revenue$1.42B$1.42B+6.9% vs Q4 2011 Net Income$292.10M$292.10M−2.7% vs Q4 2011 EPS Diluted$1.23$1.23+0.8% vs Q4 2011 Gross Profit$1,284,100,000+8.2% Operating Incomederived$445,506,000+8.9% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
Operating Cash Flowderived$507,907,000+7.2% Free Cash Flowderived$438,870,000+8.8% Margins · derivedGross margin90.6%+1.1 pt vs Q4 2011
Operating margin31.4%+0.6 pt vs Q4 2011
Net margin20.6%−2.0 pt vs Q4 2011